Niagara Falls, NY, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices.

The Attrius is a 2D quantitative dedicated PET scanner optimized for nuclear cardiology. The Attrius provides high-resolution images in tandem with robust blood flow data for analysis optimal for the latest in coronary flow reserve software, assisting the generation of accurate measurements of absolute blood flow and coronary flow reserve.

The NeuSight PET-CT is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET-CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities.

As a cost-effective and innovative system, the NeuSight PET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight PET-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.

Adel Abdullah, President of Positron stated, “We are pleased that esteemed physicians in the nuclear cardiovascular field recognize the advantages of our systems and services. These recent sales are very positive indicators of our growing momentum in the marketplace. We believe our technology, comprehensive support and unmatched value uniquely position us to advance the adoption of PET imaging and cardiovascular care." Mr. Abdullah added, "We are thrilled to work with such a distinguished physician dedicated to providing expert care. We look forward to supporting their growth and ensuring they fully utilize the capabilities of our Attrius PET and NeuSight PET-CT systems in delivering outstanding outcomes for their patients.”


About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.

Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.

Hospital Installs Homepage